G0F.F GRIFOLS ADR 1/2/EO-50

Healthcare Pharmaceuticals Frankfurt Exchange
8.86 EUR
Close of Nov 12, 2026
4.00 5.89
Market cap
EUR 7.49B
P/E
15.3x
P/B
1.27x
ROE
9.0%
Dividend yield
1.71%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is G0F.F undervalued?

Graham number
Price8.86
Graham value9.54
Discount7.1%

G0F.F trades 7.1% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GRIFOLS ADR 1/2/EO-50 fundamental analysis

No fundamental analysis for GRIFOLS ADR 1/2/EO-50 yet.

GRIFOLS ADR 1/2/EO-50 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GRIFOLS ADR 1/2/EO-50

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and mark…

Full company profile